476 Background: Atezo+ bev in pts with unresectable HCC who had not received prior
systemic therapy has shown statistically significant and clinically meaningful improvement in …

Background Ph 1b data has shown promising efficacy and safety for atezo+ bev in
unresectable HCC pts who have not received prior systemic therapy. Here, we report the …

4071 Background: Based on IMbrave150 (NCT03434379) results, atezo+ bev has been
approved in> 60 countries for pts with unresectable HCC who have not received prior …

Background: Agents targeting angiogenesis or PD-L1/PD-1 signalling represent 2 types of
approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab …

Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Background & Aims IMbrave150 demonstrated that atezolizumab plus bevacizumab led to
significantly improved overall survival (OS) and progression-free survival (PFS) compared …

Background IMbrave150 is a phase III trial that assessed atezolizumab+ bevacizumab
(ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular …

4585 Background: The IMbrave150 pivotal study in unresectable HCC showed superiority of
atezolizumab+ bevacizumab (atezo+ bev) vs sorafenib for OS and PFS. Based on these …

TPS4141 Background: Hepatocellular carcinoma (HCC) is a lethal disease with the highest
mortality-to-incidence ratio of any solid tumor. The current standard of care for 1L treatment …

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and remains a
significant cause of cancerrelated death globally. The incidence of HCC has been on the …